Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 626-630, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-690938
ABSTRACT
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment. In this review, the history, structure and mechanism of action of CAR-T, as well as the current status and challenges of CAR-T immunotherapy in acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma are summarized.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Receptors, Antigen, T-Cell
/
T-Lymphocytes
/
Immunotherapy, Adoptive
/
Antigens, CD19
/
Hematologic Neoplasms
/
Immunotherapy
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS